Why Is AMGEN INC (AMGN) Stock Down Today?

AMGN stock fell 9.21% to $396.97 on Tuesday, marking one of the largest single-session declines in recent months. The drop came amid a broader market reaction to Novartis’ disappointing drug trial results and a shift in risk-reward dynamics for biotech stocks. The stock opened with a -4.9% gap from the previous close and continued to fall throughout the session, reaching a low of $396.89 before stabilizing slightly in the final minutes.

What Happened

The decline was driven by a combination of sector-wide concerns and specific developments affecting Amgen. A key factor was the broader market reaction to Novartis’ recent drug trial results, which caused a ripple effect across biotech names. Amgen itself reported positive Phase 3 DeLLphi-305 study results for its drug combination in treating small cell lung cancer, but the news came after the market had already turned bearish. Analysts from BMO downgraded Amgen to Market Perform, citing a shift in risk-reward dynamics, while Cantor Fitzgerald reiterated a Neutral stance with a $400 price target. Additionally, recent insider sales by senior executives and a lack of strong follow-through from recent trial announcements contributed to the selling pressure.

What The Data Shows

The intraday session showed a sharp decline from the open, with volume reaching 1.2 million shares, or 0.4 times the 3-month average. The stock is currently trading near its 52-week low of $269.77, having fallen from a high of $447.03 earlier in the year. Over the last 8 sessions, the stock has declined 0.7% to $437.32. Recent insider transactions include three sales totaling $4.1 million, with the most recent filing on August 13. The 52-week tape also showed one fresh 52-week high and 10 fresh 52-week lows on September 8. The stock’s beta of 0.43 suggests it is less volatile than the broader market, but recent sentiment has deteriorated, with a 7-day average of 49/100 compared to a 30-day average of 56/100.

What To Watch

Investors should monitor the company’s next earnings report, which is not currently scheduled. In the near term, the focus will be on analyst coverage and how the market reacts to the latest trial results and broader biotech sector dynamics.